Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (1191-1200 of 1,281) with videos related to

Pageof 129
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancerDoreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, et al.
JTO Clinical and Research Reports|December 17, 2021
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and EfficacySally C M Lau, Malcolm Ryan, Jessica Weiss, et al.
The Review of Scientific Instruments|September 1, 2022
Spatially resolved diagnostics for optimization of large ion beam sourcesG Serianni, E Sartori, R Agnello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysisV A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
The Lancet. Oncology|December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialCharles Butts, Mark A Socinski, Paul L Mitchell, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patientsYuchen Li, Jennifer Law, Lisa W Le, et al.
Cell Reports|June 8, 2025
Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancerChenchu Lin, Thomas L Pulliam, Jenny J Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Rheumatology (Oxford, England)|February 25, 2023
Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measureSusan Bridgewater, Michael A Shepherd, Jill Dawson, et al.
Pageof 129

Showing results (1191-1200 of 1,281) with videos related to

Sort By:
Pageof 129
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancerDoreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, et al.
JTO Clinical and Research Reports|December 17, 2021
Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and EfficacySally C M Lau, Malcolm Ryan, Jessica Weiss, et al.
The Review of Scientific Instruments|September 1, 2022
Spatially resolved diagnostics for optimization of large ion beam sourcesG Serianni, E Sartori, R Agnello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysisV A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
The Lancet. Oncology|December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialCharles Butts, Mark A Socinski, Paul L Mitchell, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patientsYuchen Li, Jennifer Law, Lisa W Le, et al.
Cell Reports|June 8, 2025
Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancerChenchu Lin, Thomas L Pulliam, Jenny J Han, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2021
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLCYi-Long Wu, Thomas John, Christian Grohe, et al.
Rheumatology (Oxford, England)|February 25, 2023
Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measureSusan Bridgewater, Michael A Shepherd, Jill Dawson, et al.
Pageof 129